Anirban Basu

faculty photo
Professor, Health Services
Professor, Pharmacy (primary appt.)
Adjunct Professor, Economics

Education

PhD   University of Chicago, 2004   (Health Economics, Public Policy)
MS   University of North Carolina (Chapel Hill), 1999   (Biostatistics)
MS   University of Toledo, 1997   (Pharmaceutical Sciences)
BS   Jadavpur University, 1995   (Pharmaceutical Sciences)

Contact Info

email:   basua@uw.edu
web site:   http://faculty.washington.edu/basua/

office:   H-670G, Health Sciences Building

address:
Magnuson Health Sciences Center
1959 NE Pacific St.
Seattle, WA 98195-7660

campus box:   357660
voice:   206-616-2986
fax:   206-543-3964

About

Dr. Basu is an associate professor in the Departments of Health Services and Pharmacy at the University of Washington, Seattle. He is also a faculty research fellow at the National Bureau of Economic Research. Dr. Basu's research interests lie in revealing heterogeneity in clinical and economic outcomes in order to establish the value of individualized care. His work has focused on translating such information for public policy using innovative methods in comparative effectiveness and cost-effectiveness research. Dr. Basu has developed methods dealing with issues related to modeling health expenditure data, which is renowned for its idiosyncrasies and the difficulties it poses for applied health services researchers. He has also worked on methods used for making causal inferences using observational data. His applied work spans many dimensions that include analyzing the cost-effectiveness of prostate cancer treatments, establishing the value of individualized care based on patient preferences, developing models to predict quality of life of patients with multiple comorbidities, measuring the effect of patients' health on the quality of life of their partners, developing novel methods to estimate long-term costs of prostate cancer therapies, estimating the future value of research in diagnosing and finding a cure for Duchenne muscular dystrophy, developing simulation models for evaluating the cost-effectiveness of pharmacological treatment algorithms in schizophrenia, and comparative effectiveness research on the dynamic intensification of glucose lowering therapies in diabetes.

Dr. Basu is an Associate Editor for both Health Economics and the Journal of Health Economics and has taught courses on decision analysis, cost-effectiveness analysis and health services research methods. He has received numerous recognitions for his work throughout his career and for which he remains grateful to his mentors and peers: the NARSAD Wodecroft Young Investigator Award (2005), the Research Excellence Award for Methodological Excellence (2007) and the Bernie O'Brien New Investigator Award (2009) from the International Society for Pharmacoeconomics and Outcomes Research, the Alan Williams Health Economics Fellowship (2008) from the University of York, UK and the Labelle Lectureship in Health Economics (2009) from McMaster University, Canada.


Health econometrics; cost-effectiveness; comparative effectiveness and value of information analyses; quality of life; spill-over effects; substantive focus on cancer, mental health and diabetes

  • HSERV 525
    Advanced Health Services Research Methods III - Causal Inference Using Observational Data


Basu A. Financing cures in the United States. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):1-4. doi: 10.1586/14737167.2015.990887. Epub 2014 Dec 6.  PMID: 25482146
  

Basu A, Gore JL. Are Elderly Patients With Clinically Localized Prostate Cancer Overtreated? Exploring Heterogeneity in Survival Effects. Med Care. 2015 Jan;53(1):79-86.  PMID: 25397964
  

Basu A. ESTIMATING PERSON-CENTERED TREATMENT (PeT) EFFECTS USING INSTRUMENTAL VARIABLES: AN APPLICATION TO EVALUATING PROSTATE CANCER TREATMENTS. J Appl Econ (Chichester Engl). 2014 June/July;29(4):671-691.  PMID: 25620844    PMCID: PMC4300990
   

Basu A, Chan KC. Can we make smart choices between ols and contaminated iv methods? Health Econ. 2014 Apr;23(4):462-72. doi: 10.1002/hec.2926. Epub 2013 Jun 13.  PMID: 23765683
  

Basu A, Jena AB, Goldman DP, Philipson TJ, Dubois R. HETEROGENEITY IN ACTION: THE ROLE OF PASSIVE PERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH. Health Econ. 2013 Oct 9. doi: 10.1002/hec.2996. [Epub ahead of print]  PMID: 24123568    PMCID: PMC4282978
   

2011
Chair, thesis committee for Vasanthi Gowri
An analysis of 30 day readmissions to an urban community hospital

Comparative Effectiveness of Dynamic Patterns of Glucose Lowering Therapies
University of Chicago
PI:   Basu           Dates:    6/1/2015 - 5/31/2016

Innovative Methods for Modeling Lognitudinal Medical Costs
Northwestern University
PI:   Basu           Dates:    9/1/2014 - 8/31/2015

Personalized Medicine Economics Research PriMER
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
PI:   Veenstra           Dates:    7/1/2014 - 6/30/2015

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity
National Institutes of Health (NIH)
PI:   Zatzick           Dates:    7/1/2014 - 6/30/2019

Comparative Effectiveness of Dynamic Patterns of Glucose Lowering Therapies
University of Chicago
PI:   Basu           Dates:    6/1/2014 - 5/31/2015

Personalized Medicine Economics Research (PriMER)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
PI:   Veenstra           Dates:    10/1/2013 - 9/30/2018

Innovative Methods for Modeling Lognitudinal Medical Costs
Northwestern University
PI:   Basu           Dates:    9/1/2013 - 8/31/2014

Comparative Effectiveness of Dynamic Patterns of Glucose Lowering Therapies
University of Chicago
PI:   Basu           Dates:    6/1/2013 - 5/31/2014

A randomized trial of a structured method for prioritizing cancer research
Fred Hutchinson Cancer Research Center (FHCRC)
PI:   Carlson           Dates:    6/1/2013 - 11/30/2015

Instrumental Variable Methods for Censored Cost Data and an Application in Prostate Cancer
National Cancer Institute (NCI)
PI:   Basu           Dates:    4/1/2013 - 3/31/2014

A Comprehensive Probabilistic-Micro-Simulation Model to Assess Cost-Effectiveness
National Institute of Mental Health (NIMH)
PI:   Basu           Dates:    12/1/2012 - 11/30/2013

Monoclonal Antibodies in Cancer Care: Is Underinsurance An Access Barrier?
University of Chicago
PI:   Basu           Dates:    8/1/2012 - 7/31/2013

Instrumental Variable Methods for Censored Cost Data and an Application in Prostate Cancer
National Cancer Institute (NCI)
PI:   Basu           Dates:    4/1/2012 - 3/31/2013

Variation in Inpatient Costs for Severe Pediatric Traumatic Brain Injury (TBI)
National Institutes of Health (NIH)
PI:   Vavilala           Dates:    4/1/2012 - 3/31/2013

Innovative Methods for Modeling Longitudinal Medical Costs
Northwestern University
PI:   Basu           Dates:    12/28/2011 - 8/31/2016

A Comprehensive Probabilistic-Micro-Simulation Model to Assess Cost-Effectiveness
National Institute of Mental Health (NIMH)
PI:   Basu           Dates:    12/1/2011 - 11/30/2012

Comparative Effectiveness of Dynamic Patterns of Glucose Lowering Therapies
University of Chicago
PI:   Kessler           Dates:    7/1/2011 - 6/30/2015

Instrumental Variable Methods for Censored Cost Data and an Application in Prostate Cancer
National Cancer Institute (NCI)
PI:   Basu           Dates:    6/1/2011 - 5/31/2014

Monoclonal Antibodies in Cancer Care: Is Underinsurance An Access Barrier?
University of Chicago
PI:   Basu           Dates:    3/6/2011 - 7/31/2013

Advancing Instrumental Variable Methods in Comparative Effectiveness Research
National Cancer Institute (NCI)
PI:   Basu           Dates:    1/1/2011 - 8/31/2013

A Comprehensive Probabilistic-Micro-Simulation Model to Assess Cost-Effectiveness
National Institute of Mental Health (NIMH)
PI:   Basu           Dates:    1/1/2011 - 5/31/2013

Graduate Certificate in Comparative Effectiveness Research

Comparative effectiveness research is a growing field that aims to generate evidence to improve health care decisions for patients and providers. It examines the benefits and risks of different medical or healthcare interventions, including drugs and medical technology. The results of these comparison studies are used by medical professionals to make better informed healthcare decisions and thereby improve patient care.